Ken Griffin’s Citadel increased its Johnson & Johnson holdings by 146% amid strong fund performance and risk-aware strategies.
Citadel, the hedge fund overseeing $69 billion, raised its stake in Johnson & Johnson by 146% in the first quarter, now holding 1.93 million shares. The move follows Citadel’s recognition as the most profitable hedge fund for the fourth consecutive year, with positive returns across strategies in early 2024.
Griffin’s investment approach emphasizes in-depth research and risk management, aligning with J&J’s status as a Dividend King. The company recently spun off its consumer health unit, Kenvue, to focus on pharmaceuticals and medtech.
The increased position reflects confidence in J&J’s stability and long-term growth potential, particularly for risk-averse investors.